Navigation Links
Experimental Blood Thinner Given Before Surgery Shows Benefit
Date:1/17/2012

TUESDAY, Jan. 17 (HealthDay News) -- An experimental anti-blood-clotting drug can serve as a replacement for other drugs such as Plavix in the days before heart surgery, a new study has found.

The intravenous drug cangrelor appears to have the potential to serve as a "bridge" medication for heart patients to take in the several days before procedures such as coronary artery bypass grafting, the study authors reported.

Anti-clotting drugs, also referred to as antiplatelet therapy or anticoagulants -- including clopidogrel, known by the brand name Plavix -- are often given to heart patients to prevent dangerous vessel-clogging blood clots. But they can cause too much bleeding during surgery, and guidelines suggest that doctors stop treatment with them in the five to seven days before an operation.

In the new study, Dr. Dominick Angiolillo of the University of Florida, Jacksonville, and colleagues gave cangrelor or a placebo to 210 patients who were about to undergo coronary artery bypass grafting. The patients had been treated with a thienopyridine (such as Plavix) but went off the drugs prior to surgery as recommended, then received cangrelor or placebo for at least 48 hours until one to six hours before surgery.

Angiolillo's team found that excessive bleeding related to surgery wasn't much more likely in the patients who took the drug (11.8 percent) compared to those who took the placebo (10.4 percent). Major bleeding problems before surgery were rare, while those who took cangrelor had more minor bleeding problems, according to the report published in the Jan. 18 issue of the Journal of the American Medical Association.

The investigators also found that the patients who took cangrelor reached levels of platelet inhibition that are linked to a lower risk of problems such as clots.

The findings make sense, said Dr. Gregg Stone, a heart specialist and professor of medicine at Columbia Univers
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Wolfson Foundation awards £20 million to UCL for experimental neurology center
2. Novel experimental agent is highly active in CLL patients, interim study shows
3. Experimental Drug for Irregular Heart Rhythm Raises Death Risk: Study
4. Experimental Drug Slims Obese Monkeys
5. Experimental Psoriasis Drug Bests Older Treatment
6. Experimental Vaccine Shows Promise for Lung Cancer: Study
7. Experimental vaccine protects monkeys from blinding trachoma
8. Experimental MS Drug Shows Promise
9. Researchers create new experimental vaccine against chikungunya virus
10. Experimental Drug Promising Against Tough-to-Treat Asthma
11. University Hospitals Case Medical Center to begin clinical trial on experimental anti-TB drug
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Blood Thinner Given Before Surgery Shows Benefit  
(Date:7/30/2014)... Volunteers from the Church of Scientology of Denmark ... with massive distribution of Truth About Drugs ... on Strøget, the famous Copenhagen walking street. Popular ... its ambiance, some quarter of a million people stroll ... , These activities are part of a coordinating effort ...
(Date:7/30/2014)... fuel cancer as well as evolutionary changes in a ... occur randomly throughout the genome. , However, recent studies ... of multiple mutations that arise simultaneously and in close ... are frequently found in regions where chromosomal rearrangements take ... Cell Reports , may one day lead to new ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 ... of authentication, access management and secure communications solutions ... Imprivata OneSign ® is the most widely selected ... McKesson Paragon or Horizon electronic medical records (EMR) ... increase of about 11 percent in the last ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery is happy ... on July 30th. After months of planning, Dr. Hamilton ... state-of-the-art suite, located only steps away from the original ... one-on-one patient comfort, shorter wait times, and generally a ... new office-suite will continue to provide the same wide ...
(Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3
... OAKLAND, Calif., Aug. 11 The American Heart ... Oakland and,Stanford University Medical Center $3.89 million over ... heart research center that aims to define,optimal clinical ... chronic,heart failure., The Kaiser Permanente Division of ...
... Aug. 11 Perrigo Company,(Nasdaq: PRGO ; ... chewable tablets (famotidine 10 mg; calcium carbonate 800mg;,magnesium ... under their store,brand labels. Perrigo won a successful ... to Pepcid Complete(R) marketed by,Johnson & Johnson - ...
... Inc., a,global leading manufacturer of orthodontic products and ... a full-service,orthodontic laboratory. The O2 Orthodontic Laboratory is ... Carlsbad, CA., "The O2 Orthodontic Laboratory is ... it allows the Company to further its,commitment to ...
... (GICD) and UCSF have identified a key regulatory factor ... the extensive network of arteries, veins, and capillaries that ... research, published in the latest issue of Developmental ... for a wide variety of diseases, such as heart ...
... examinations of PSA screening in younger men, a study published ... of men under age 50 reported undergoing a prostate specific ... year, yet only one in three young black men reported ... , Overall, that,s pretty good news for white men at ...
... chemical might lead to drug treatments for humans , , SUNDAY, ... of mice resistant to diet-induced obesity. , The findings ... in people. They also shed light on the brain circuitry ... energy (i.e., food) an animal takes in and how quickly ...
Cached Medicine News:Health News:Kaiser Permanente - Stanford Heart Research Center Funded to Study Treatment Outcomes 2Health News:Kaiser Permanente - Stanford Heart Research Center Funded to Study Treatment Outcomes 3Health News:Kaiser Permanente - Stanford Heart Research Center Funded to Study Treatment Outcomes 4Health News:Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide 2Health News:Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide 3Health News:Ortho Organizers(R) Opens a Full-Service Orthodontic Laboratory 2Health News:Gladstone scientists identify single microRNA that controls blood vessel development 2Health News:Gladstone scientists identify single microRNA that controls blood vessel development 3Health News:Study finds more PSA screening awareness needed among high-risk groups 2Health News:Scientists Create Mice Resistant to Obesity 2Health News:Scientists Create Mice Resistant to Obesity 3
(Date:7/30/2014)... 2014 Cynosure, Inc. (NASDAQ: ... for non-invasive and minimally invasive applications, today announced that the ... Officer and Chief Financial Officer Timothy W. Baker ... 53, will continue to serve as CFO and will take ... remains Chairman and Chief Executive Officer. "Tim ...
(Date:7/30/2014)... CLARA, Calif. , July 30, 2014 ... economy, released a study today that examines ... biopharma and medical device companies.  According to the annual ... saw the biggest potential returns since SVB started tracking ... year of the IPO.  Built on solid healthcare M&A ...
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
Breaking Medicine Technology:Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... , SALT LAKE CITY, Dec. 16 ... "Company"), a medical device company engaged in the development and ... that Joe Pepper, PhD, has been appointed to the TechniScan ... "Joe has extensive experience running small to large medical devices ...
... EVANSTON, Ill., Dec. 16 Naurex Inc., a new clinical ... disorders based on its novel GFPA NMDA receptor modulators, today ... of its lead compound GLYX-13 and has successfully dosed the ... functional partial agonist (GFPA) selective modulator of the NMDA receptor, ...
Cached Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3
... K-ASSAY ASO / RF / ... to be used as a ... concentration for monitoring the performance ... Rheumatoid Factor (RF), and C-Reactive ...
... of benchtop microcentrifuges with the 5424. ... aerosol-tight rotor and a unique, contoured ... ,Model 5424 expands its application range ... microcentrifuge tubes, miniprep spin columns and ...
... hand, the Jarvik 2000 pump is about the ... titanium shell sits a direct-current motor, a rotor ... moving part: a small, spinning titanium impeller that ... 7 liters per minute. Rather than take over ...
... VentrAssist is a new third generation cardiac assist ... heart transplants for patients suffering heart failure., ,It ... left ventricle of the diseased heart to help ... restoring a better quality of life. , ,It ...
Medicine Products: